DexCom Inc. closed 48.20% below its 52-week high of $142.00, which the company reached on March 26th.

The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...

DexCom Inc. closed 46.96% short of its 52-week high of $142.00, which the company achieved on March 26th.

Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...

DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 8% to $74.17 per share. This run-up ...

Jake Leach caught up with MedTech Dive during the ATTD conference to discuss new data on the company’s glucose monitors.

Dexcom, the local maker of continuous glucose monitors, received a warning letter from the Food and Drug Administration last ...

Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platform, will ingest glucose data ...

The Joseph P. Addabbo Family Health Center (JPAFHC) in Southeast Queens is making significant strides in diabetes care in New ...

In a new study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated the accuracy of the 15.5-day ...